Abstract:38 Background: 18 F-Flotufolastat ( 18 F-rhPSMA-7.3) is a newly approved high affinity PSMA-targeting PET radiopharmaceutical for diagnostic imaging in patients with prostate cancer (PCa). SPOTLIGHT (NCT04186845) evaluated 18 F-flotufolastat in patients with recurrent PCa. Here, we report available SPOTLIGHT data to assess the impact of 18 F-flotufolastat on planned treatment after curative-intent primary therapy. Methods: Patients underwent PET 50–70 min after IV administration of 296 MBq 18 F-flotufolastat. The protocol instructed onsite investigators to record patients’ management plans (MP) before and after 18 F-flotufolastat PET. These MP were compared and categorized as: ‘no change’, ‘major change’, ‘other change’, ‘additional information required’ or ‘intended plan not valid’. A ‘major change’ was defined as a change to treatment modality (e.g., salvage radiation therapy [RT] to systemic therapy), while ‘other change’ represented a change within a modality (e.g., modified RT field). Plans categorized as ‘no change’, ‘major change’ or ‘other change’ were considered evaluable. All imaging data were subsequently submitted for blinded image evaluation (BIE) by 3 central readers. Results: Of 389 patients who had 18 F-flotufolastat PET, 97 had sufficient MP data for evaluation. These 97 patients were comparable to the overall population in terms of prior treatment (84% vs 79%, respectively, were post-prostatectomy), Gleason Score (63% vs 60% had Score 7), and median baseline PSA (0.8 vs 1.1 ng/mL). Moreover, BIE data show the detection rate in this subgroup (81/97; 84%) to be equivalent to that in the overall population (322/389; 83%). Most patients, 86/97 (89%) had a change to their MP post-scan. A ‘major change’ was noted for 78 (80%) patients, while 8 (8.2%) had an ‘other change’ (Table). Onsite imaging reads show that both positive and negative 18 F-flotufolastat scans influenced MP. While 88% of revisions occurred after a positive scan, 75% of those whose MP were revised to watchful waiting (WW) had negative scans. All patients with MP revised from salvage therapy to non-curative systemic therapy had distant/extrapelvic 18 F-flotufolastat-avid lesions. Conclusions: 18 F-Flotufolastat located recurrence sites in the majority of patients with recurrent PCa, frequently resulting in major changes to MP. Treatment based on visualization of 18 F-flotufolastat-avid lesions may facilitate optimal targeting of recurrence sites and avoid futile salvage therapy. Future studies of the outcome of such MP changes are warranted. Clinical trial information: NCT04186845 . [Table: see text]

Negative 18 F-Piflufolastat PET/CT, But Positive 18 F-Fluciclovine PET/CT, in a Patient With Biochemically Recurrent Prostate Cancer

Negative 18F-Piflufolastat PET/CT, But Positive 18F-Fluciclovine PET/CT, in a Patient With Biochemically Recurrent Prostate Cancer

18F-Fluciclovine PET Detected Early Tumor Recurrence in Prostatectomy Bed With Low PSA of 0.3 ng/mL But Negative on 18F-PSMA PET Scan

Mismatched Lesions on 18F-FDG PET and 18F-Fluciclovine PET Images in a Patient With Metastatic Prostate Small Cell Carcinoma

68Ga-PSMA-11 PET Identified Tumor Recurrence in Prostatectomy Bed With Rising PSA of 0.9 ng/mL but Negative on MRI and 18F-Fluciclovine PET Scan

18F-Fluciclovine PET metabolic imaging reveals prostate cancer tumour heterogeneity associated with disease resistance to androgen deprivation therapy

Real-world evidence of 18F-fluciclovine Positron emission tomography/computed tomography performance for recurrent prostate cancer in the Veterans Affairs Health System

Evaluating appropriateness of 18F-fluciclovine PET/CT relative to standard of care imaging guidelines and the impact of ADT on positivity: a prospective study in 62 Veterans Administration patients at a single institution

Recurrent prostate cancer detection with anti-3-[18F]FACBC PET/CT: comparison with CT

Imaging Characteristics of Coexisting Metastatic Papillary Thyroid Cancer and Prostate Cancer on 18F-Fluciclovine and 68Ga-PSMA-11 PET/CT

Salvage Radiotherapy Management Decisions in Postprostatectomy Patients with Recurrent Prostate Cancer Based on 18F-Fluciclovine PET/CT Guidance

18F-Fluciclovine Positron Emission Tomography in Men With Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Planning to Undergo Salvage Radiation Therapy: Results from LOCATE

18F-DCFPyL PET/CT for Initially Diagnosed and Biochemically Recurrent Prostate Cancer: Prospective Trial with Pathologic Confirmation

True-Positive 18F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study

Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer

Incidental Detection of Urothelial Carcinoma on 18F-Fluciclovine PET/CT

Role of 18F-Dcfpyl PET/CT in Patients with Suspected Prostate Cancer.

Impact of 18 F-flotufolastat PET on management of patients with recurrent prostate cancer: Data from the SPOTLIGHT study.

Laparoscopic Port-Site Metastasis From Prostate Cancer on 18F-Fluciclovine PET/CT

Detection of Adenocarcinoma of the Colon on 18F-Fluciclovine PET/CT

Bone and Lymph Node Flare to Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer on 18F–Prostate-Specific Membrane Antigen PET/CT With Decreasing Prostate-Specific Antigen of 0.7 ng/mL